atai Life Sciences (ATAI) announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of BPL-003, for treatment-resistant depression. The findings show that a single dose of BPL-003, when given to patients who were also taking defined selective serotonin reuptake inhibitors, was well-tolerated, with rapid and durable antidepressive effects of up to three months with an average in-clinic treatment time of less than two hours following dosing. The results are also consistent with initial results from Part 1 of the study, which investigated BPL-003 as a monotherapy. Data from that study showed that a single dose of BPL-003 was well-tolerated and produced a rapid and lasting antidepressant effect for up to three months after dosing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- ATAI Life Sciences: Positioned for Leadership in Scalable Psychedelic Psychiatry with Strong Financial Foundation and Promising Clinical Milestones
- ATAI Life Sciences: Strong Buy Rating Backed by Promising Trials and Robust Financial Health
- ATAI Life Sciences: Buy Rating Backed by Promising Pipeline and Strong Cash Position Amid Upcoming Catalysts
- ATAI Life Sciences: Strong Financial Position and Promising Pipeline Drive Buy Rating
- VA secretary wants to find answers on psychedelics therapies, Politico says
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue